EXHIBIT 99







8229 Boone Boulevard,
Suite 802                                            COMPANY CONTACT:
Vienna, VA  22182.  USA                              Gavin de Windt
Telephone (703) 506-9460                             CEL-SCI Corporation
www.cel-sci.com                                      (703) 506-9460

CEL-SCI Announces That the NYSE MKT Approves Plan

VIENNA,  VA, February 27, 2017 - CEL-SCI  Corporation  (NYSE MKT: CVM) announces
that the NYSE MKT (the  "Exchange")  has  accepted the  Company's  plan to bring
itself into compliance with the Exchange's continued listing standards.

The Company  previously  received  notice from the Exchange on December 9, 2016,
indicating  the Company is below  compliance  with Section  1003(a)(i),  Section
1003(a)(ii) and Section  1003(a)(iii)  since it reported a stockholders'  equity
deficit  as of June 30,  2016 and had a net losses in its 5 most  recent  fiscal
years ended  September  30, 2015.  The Company was afforded the  opportunity  to
submit a plan to regain compliance, and on January 9, 2017 the Company submitted
its plan to the Exchange.

On February  24, 2017 the  Exchange  notified  the Company  that it accepted the
Company's  plan of  compliance  and granted  the Company  until June 11, 2018 to
regain  compliance  with the continued  listing  standards.  The Company will be
subject  to  periodic  review  during  this  period.  Failure  to make  progress
consistent  with the plan or to regain  compliance  with the  continued  listing
standards by the end of the period could  result in the Company  being  delisted
from the NYSE MKT. The Company may then appeal a staff determination to initiate
such proceedings in accordance with the exchange's Company Guide.

About CEL-SCI Corporation

CEL-SCI's  work is focused on finding the best way to activate the immune system
to fight cancer and infectious  diseases.  The Company has operations in Vienna,
Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release  contains  forward-looking  statements  within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange Act of 1934, as amended.  When used in this press  release,
the words  "intends,"  "believes,"  "anticipated,"  "plans" and  "expects,"  and
similar expressions,  are intended to identify forward-looking  statements. Such
statements  are  subject  to risks and  uncertainties  that could  cause  actual
results to differ materially from those projected.  Such statements include, but
are not  limited  to,  statements  about the terms,  expected  proceeds,  use of
proceeds and closing of the offering.  Factors that could cause or contribute to
such  differences  include,  an  inability to  duplicate  the  clinical  results
demonstrated in clinical studies,  timely  development of any potential products
that  can be  shown to be safe and  effective,  receiving  necessary  regulatory
approvals,   difficulties  in  manufacturing  any  of  the  Company's  potential
products,  inability  to raise the  necessary  capital and the risk  factors set
forth from time to time in CEL-SCI's  filings with the  Securities  and Exchange
Commission,  including but not limited to its report on Form 10-K and 10-K/A for
the year ended  September  30, 2016.  The Company  undertakes  no  obligation to
publicly release the result of any revision to these forward-looking  statements
which may be made to reflect the events or  circumstances  after the date hereof
or to reflect the occurrence of unanticipated events.\